Recurrent Breast Carcinoma Clinical Trials

95 clinical trials for Recurrent Breast Carcinoma across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer — RECRUITING · PHASE1
• Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial — RECRUITING · PHASE2
• 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer — RECRUITING · PHASE2
• Study on Recurrent Breast Cancer and Repeated Radiation Therapy — RECRUITING · NA
• Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer — RECRUITING
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer — RECRUITING · PHASE1
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity — RECRUITING · PHASE3
• Paclitaxel Therapeutic Drug Monitoring in Cancer Patients — SUSPENDED
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations — ACTIVE_NOT_RECRUITING · PHASE2
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic — ACTIVE_NOT_RECRUITING · PHASE3
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer — COMPLETED · PHASE1
• Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU — TERMINATED · PHASE3
• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer — COMPLETED · PHASE3
• Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer — COMPLETED · PHASE2
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian — ACTIVE_NOT_RECRUITING · PHASE1
• Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy — ACTIVE_NOT_RECRUITING
• Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer — ACTIVE_NOT_RECRUITING
• Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease — TERMINATED · PHASE1
• Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases — COMPLETED · PHASE2
• ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors — COMPLETED · PHASE1
• Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer — COMPLETED · PHASE3
• Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences — TERMINATED · PHASE1
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer — COMPLETED · PHASE3
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer — TERMINATED · PHASE1
• Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer — COMPLETED · PHASE3
• T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer — COMPLETED · PHASE1
• Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer — WITHDRAWN · PHASE1
• Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer — COMPLETED · PHASE2
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction — COMPLETED · PHASE1
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer — TERMINATED · PHASE1
• Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer — COMPLETED · PHASE1
• Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — COMPLETED · PHASE1
• Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer — COMPLETED · PHASE1
• Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer — COMPLETED · PHASE1
• SMMART Adaptive Clinical Treatment (ACT) Trial — WITHDRAWN · PHASE1
• Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer — COMPLETED · PHASE1
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer — COMPLETED · PHASE2
• Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer — COMPLETED · NA
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer — COMPLETED · PHASE1

Refine this search